Anzeige
Erschienen in:
01.06.2015 | VASCULAR AND INTERVENTIONAL RADIOLOGY
Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer
Erschienen in: La radiologia medica | Ausgabe 6/2015
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.
Materials and methods
Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.
Results
Time to intrahepatic progression was median 11 months (range 1.6–184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.
Conclusions
In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.